In 2015, one of us published a peer-reviewed study, together with colleagues at the University of California, San Francisco, replicating prior research from the US Food and Drug Administration (FDA) detecting a designer stimulant, β-methylphenylethylamine, in sports, weight loss, and “cognitive function” supplements sold in the United States. The confirmatory study prompted the FDA to take enforcement action against companies selling the stimulant as a dietary ingredient. One of the companies that received an FDA warning letter sued the study’s authors for $200 million in damages for libel, claiming, without supporting scientific evidence, that multiple statements in the article were false. Following intrusive discovery and a 7-day jury tri...
The public has lacked convincing documentary evidence of a long-suspected drug company practice: pro...
This Article examines the possible inequity of the treatment of licensees\u27 rights in tort litigat...
This Article focuses on one emerging aspect of tort litigation against pharmaceutical manufacturers ...
In 2015, one of us published a peer-reviewed study, together with colleagues at the University of Ca...
In the 1993 landmark case Daubert v. Merrell Dow Pharmaceuticals, the United States Supreme Court ar...
Rule 10b-5, a powerful weapon against any publicly-listed company whose share price drops on adverse...
Two years ago, the U.S. Food and Drug Administration (FDA) filed a lawsuit in a federal district cou...
A number of high-profile toxic tort cases, such as silicone breast implants, have followed a familia...
Fischer says he believes that the uneasy relationship between law and science is likely to continue ...
The thesis of this article is that the Supreme Court decision in Daubert v. Merrell Dow Pharmaceutic...
Clinical investigator fraud is a very real problem, and falls squarely within FDA\u27s mandate to pr...
In June 2006, after having granted certiorari and hearing oral arguments, the United States Supreme ...
Merck sought protection under a statutory exemption from claims of patent infringement brought by In...
In 2012, the U.S. Court of Appeals for the Second Circuit handed down a landmark decision in the cas...
On its face, Daubert v. Merrell Dow Pharmaceuticals was about as easy a case as the Supreme Court ge...
The public has lacked convincing documentary evidence of a long-suspected drug company practice: pro...
This Article examines the possible inequity of the treatment of licensees\u27 rights in tort litigat...
This Article focuses on one emerging aspect of tort litigation against pharmaceutical manufacturers ...
In 2015, one of us published a peer-reviewed study, together with colleagues at the University of Ca...
In the 1993 landmark case Daubert v. Merrell Dow Pharmaceuticals, the United States Supreme Court ar...
Rule 10b-5, a powerful weapon against any publicly-listed company whose share price drops on adverse...
Two years ago, the U.S. Food and Drug Administration (FDA) filed a lawsuit in a federal district cou...
A number of high-profile toxic tort cases, such as silicone breast implants, have followed a familia...
Fischer says he believes that the uneasy relationship between law and science is likely to continue ...
The thesis of this article is that the Supreme Court decision in Daubert v. Merrell Dow Pharmaceutic...
Clinical investigator fraud is a very real problem, and falls squarely within FDA\u27s mandate to pr...
In June 2006, after having granted certiorari and hearing oral arguments, the United States Supreme ...
Merck sought protection under a statutory exemption from claims of patent infringement brought by In...
In 2012, the U.S. Court of Appeals for the Second Circuit handed down a landmark decision in the cas...
On its face, Daubert v. Merrell Dow Pharmaceuticals was about as easy a case as the Supreme Court ge...
The public has lacked convincing documentary evidence of a long-suspected drug company practice: pro...
This Article examines the possible inequity of the treatment of licensees\u27 rights in tort litigat...
This Article focuses on one emerging aspect of tort litigation against pharmaceutical manufacturers ...